Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. [electronic resource]
Producer: 20130503Description: 1007-11 p. digitalISSN:- 1523-6536
- Acute Disease
- Adolescent
- Adult
- Aged
- Anemia, Aplastic -- mortality
- Antilymphocyte Serum -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Bone Marrow Transplantation
- Child
- Cyclophosphamide -- administration & dosage
- Drug Administration Schedule
- Drug Dosage Calculations
- Female
- Humans
- Male
- Middle Aged
- Survival Rate
- Transplantation Conditioning
- Unrelated Donors
- Vidarabine -- administration & dosage
- Whole-Body Irradiation -- adverse effects
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.